> Oculis raised CHF 20 million ($20 million) from backers including Novartis. The Swiss biotech will use the money to advance a phase 2b diabetic macular edema drug. Statement
> Themis raised €10 million ($12 million). The series C gives Themis the means to advance its pipeline of vaccines, including a phase 2 chikungunya virus candidate. Release
> Addex Therapeutics entered into a licensing agreement with Indivior for addiction drug ADX71441. Indivior is paying $5 million (€4 million) upfront and committing to up to $330 million in milestones to buy into the program. Statement
> Galapagos shared an update on its cystic fibrosis programs. Release